首页 News 正文

AstraZeneca acquires Amolyt Pharm for up to $1.05 billion

穿越夜时空簿
1301 0 0

Beijing Business Daily (Reporter Yao Qian) On March 14th, AstraZeneca announced that it had signed a final agreement to acquire Amolyt Pharma, which has developed innovative therapeutic peptides for rare endocrine and metabolic diseases. AstraZeneca stated that this acquisition will strengthen its Alexion rare disease late stage product line and expand its bone metabolism franchise. According to the transaction terms, AstraZeneca will acquire for a total consideration of up to $1.05 billion, including a prepayment of $800 million.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

穿越夜时空簿 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    3